This is Session 1 in the BioBusiness Insights: Opportunities in Regenerative Medicine series. Find out more about about all six sessions, and register for the series at a reduced rate below.
In this session, Dr Michael May, President and Chief Executive Officer, Centre for Commercialization of Regenerative Medicine (CCRM) Canada, will address the global landscape for the regenerative medicine industry and the post-pandemic sector impacts and reasons for optimism.
His presentation will include an outline of where the sector stands globally, providing market insights and trends and the impact of COVID-19. He will also address concerns that organisations may have regarding supply chains and ensuring they have capacity and capability at a local level, and will highlight the need to think globally.
Session 1 Details
Date: Thursday 30 July 2020
Time: 9:00 am – 10:00 am AEST
Format: This event will be delivered on a virtual platform – you will receive a link to join via a confirmation email following registration.
Registration:
Single session: Members $35; Non-members $45
Complete series (six sessions): Members $150; Non-members $210
Unsure if your organisation is a member? Check our member directory.
Registered? Submit a question for Session 1 ahead of time.
Speaker
Dr Michael May, President and Chief Executive Officer, CCRM, Canada
Series Facilitator
Silvio Tiziani, CEO, CCRM Australia
BioBusiness Insights is delivered in collaboration with the Centre for Commercialization of Regenerative Medicine (CCRM) Australia.
Thanks to our Premier Sponsor for this event series, the State Government of Victoria.
Thanks to our Supporting Sponsor for this event series, Cortellis.
Dr Michael May completed his PhD in Chemical Engineering at the University of Toronto in 1998 as an NSERC Scholar and was awarded the Martin Walmsley Fellowship for Technological Entrepreneurship.
He is President and Chief Executive Officer of CCRM. Prior to CCRM, Michael was the President and co-founder of Rimon Therapeutics Ltd., a Toronto-based tissue engineering company developing novel medical polymers that possess drug-like activity.
Michael sits on a number of boards and advisory committees including the ARM Foundation; AgeX Corporation; panCELLa Inc.; CCRM Enterprises; the International Advisory Board of the Swedish Centre for Advanced Medical Products (CAMP); the Poietis SAB; the Entrepreneurship Leadership Council at the University of Toronto; the Cell and Gene Therapy Insights Editorial Advisory Board; and, the Commercialization Committee of the International Society for Cell and Gene Therapy. He is the Chairman of ExCellThera Ltd.
Silvio Tiziani has played a key role in the establishment of Centre for Commercialisation of Regenerative Medicine (CCRM) Australia with the support of Canada’s CCRM, the Victorian Government and MTPConnect. Silvio is also Director, External Strategy and Planning at the Australian Regenerative Medicine Institute (ARMI). Silvio’s extensive knowledge of the research landscape is well utilised with his networks within the industry, international organisations and state and federal governments.
Silvio has extensive experience in private and public organisations, with a focus on laboratory-based services in government, private organisations, healthcare and research/academia.
In addition to qualifications that include a Bachelor of Science from Swinburne University and a Masters of Business Administration from Monash University, Silvio is also a graduate of the Australian Institute of Company Directors (GAICD). Silvio has extensive experience in financial analysis and budget management, business development, strategic planning and corporate governance along with strong interpersonal skills to lead staff.
Silvio also chairs the Ausbiotech Regenerative Medicine Advisory Group. Comprising leading representatives from industry and academia within the Australian regenerative medicine the Group provides specialist advice to Ausbiotech, Australia’s member-based biotechnology organisation, a peak body that promotes the global growth of Australian biotechnology.
